Reichindia Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 14-12-2024
- Paid Up Capital ₹ 7.00 Cr
as on 14-12-2024
- Company Age 29 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 3.03 M
as on 14-12-2024
- Satisfied Charges ₹ 5.75 Cr
as on 14-12-2024
- Revenue 0.33%
(FY 2021)
- Profit -33483.80%
(FY 2021)
- Ebitda -483.48%
(FY 2021)
- Net Worth -1515.10%
(FY 2021)
- Total Assets -39.85%
(FY 2021)
About Reichindia Pharma
The Corporate was formerly known as Reich India Bio-Application Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 7.00 Cr.
The company currently has active open charges totaling ₹3.03 M. The company has closed loans amounting to ₹5.75 Cr, as per Ministry of Corporate Affairs (MCA) records.
Gandavarapu Sharma, Srihari Kaligithi, and Tulasi Murthy serve as directors at the Company.
- CIN/LLPIN
U24230TG1995PLC021457
- Company No.
021457
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Aug 1995
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Reichindia Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gandavarapu Sharma  | Director | 13-Dec-2012 | Current |
| Srihari Kaligithi | Additional Director | 02-May-2023 | Current |
| Tulasi Murthy | Additional Director | 02-May-2023 | Current |
Financial Performance of Reichindia Pharma.
Reichindia Pharma Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 0.33% increase. The company also saw a substantial fall in profitability, with a 33483.8% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1515.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Reichindia Pharma?
In 2021, Reichindia Pharma had a promoter holding of 69.01% and a public holding of 30.99%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 31 Dec 2020 | ₹3.03 M | Open |
State Bank Of India Creation Date: 15 Oct 2016 | ₹5.28 M | Satisfied |
Others Creation Date: 31 Mar 2016 | ₹1.85 Cr | Satisfied |
How Many Employees Work at Reichindia Pharma?
Reichindia Pharma has a workforce of 99 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reichindia Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reichindia Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
